Tier 2 — strong

Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation

Pål I Holm, Øyvind Bleie, Per M Ueland, Ernst A Lien, Helga Refsum, Jan E Nordrehaug, Ottar Nygård
Arteriosclerosis, thrombosis, and vascular biology 2004 24(2):301-307

Bibliography

PubMed
PMID 14699020
DOI
10.1161/01.ATV.0000114569.54976.31
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignRCT secondary analysis
ModelHuman participants
Sample90 patients undergoing coronary angiography
InterventionB-vitamin combinations or placebo; circulating betaine measured
DurationFollow-up to 12 months; methionine tests at baseline and 3 months
EndpointsPost-load homocysteine; Betaine status

What the study showed, in plain terms

Published in 2004, this source examined homocysteine, methylation and vascular function. Design: RCT secondary analysis. Sample/model: 90 patients undergoing coronary angiography. The exposure or intervention was B-vitamin combinations or placebo; circulating betaine measured. Follow-up or treatment period: Follow-up to 12 months; methionine tests at baseline and 3 months.

Higher circulating betaine predicted a smaller homocysteine rise after methionine loading, especially before B-vitamin supplementation.

A betaine-status analysis within a vitamin trial; it does not directly test betaine supplementation.

Continue with TMG Data Center

Continue with TMG and Homocysteine: How Much Can Betaine Lower It?

Key findings

  • Higher circulating betaine predicted a smaller homocysteine rise after methionine loading, especially before B-vitamin supplementation.
  • The recorded outcome domains were Post-load homocysteine; Betaine status.
  • The result applies to the tested exposure: B-vitamin combinations or placebo; circulating betaine measured; Follow-up to 12 months; methionine tests at baseline and 3 months.

What this study can and cannot tell us

  • A betaine-status analysis within a vitamin trial; it does not directly test betaine supplementation.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysis
Marc P McRae et al. · Journal of chiropractic medicine · 2013
Tier 1
Effects of betaine supplementation on cardiovascular markers: A systematic review and Meta-analysis
Damoon Ashtary-Larky et al. · Critical reviews in food science and nutrition · 2022
Tier 2
Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans
Margreet R Olthof et al. · PLoS medicine · 2005
Tier 2
Betaine supplementation lowers plasma homocysteine in healthy men and women
Gery R Steenge et al. · The Journal of nutrition · 2003
Tier 2
Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women
Margreet R Olthof et al. · The Journal of nutrition · 2003

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology